Imexpharm Balance Sheet Health
Financial Health criteria checks 4/6
Imexpharm has a total shareholder equity of ₫2,084.6B and total debt of ₫49.4B, which brings its debt-to-equity ratio to 2.4%. Its total assets and total liabilities are ₫2,392.6B and ₫308.0B respectively. Imexpharm's EBIT is ₫381.0B making its interest coverage ratio -27.5. It has cash and short-term investments of ₫199.2B.
Key information
2.4%
Debt to equity ratio
₫49.42b
Debt
Interest coverage ratio | -27.5x |
Cash | ₫199.20b |
Equity | ₫2.08t |
Total liabilities | ₫308.04b |
Total assets | ₫2.39t |
Recent financial health updates
No updates
Recent updates
Financial Position Analysis
Short Term Liabilities: IMP's short term assets (₫1,207.1B) exceed its short term liabilities (₫308.0B).
Long Term Liabilities: IMP has no long term liabilities.
Debt to Equity History and Analysis
Debt Level: IMP has more cash than its total debt.
Reducing Debt: IMP's debt to equity ratio has increased from 0% to 2.4% over the past 5 years.
Debt Coverage: IMP's operating cash flow is negative, therefore debt is not well covered.
Interest Coverage: IMP earns more interest than it pays, so coverage of interest payments is not a concern.